| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
TCS JNK 5a (also known as JNK Inhibitor IX; TCS JNK-5a) is a novel, highly selective and potent JNK (c-Jun N-terminal Kinase) inhibitor that may have anti-cancer effects. With pIC50 values of 6.5 and 6.7, it inhibits JNK2/3. With pIC50 values of < 5.0, it has no or minimal effects on EGFR, ErbB2, VegFr2, Src, Tie-2, Alk5, c-Fms, CDK-2, GSK3β and PLK1. Human Jurkat T cells were exposed to the JNK2 and JNK3 inhibitor SC-202671, which resulted in DNA fragmentation during apoptosis, G2/M arrest, phosphorylation of Bcl-2, Mcl-1, and Bim, Δψm loss, and activation of the Bak and caspase cascade.
| Targets |
JNK3 (pIC50 = 6.7); JNK2 (pIC50 = 6.5)
|
||
|---|---|---|---|
| ln Vitro |
JNK inhibitor IX significantly lowers caspase-3 activity in human dermal fibroblasts by preventing JNK activity.[2] By preventing c-ABL from completely dephosphorylating at Ser residues, JNK inhibition by JNK inhibitor IX significantly increases apoptotic death in response to imatinib mesylate (IM).[3]
|
||
| ln Vivo |
|
||
| Enzyme Assay |
JNK2 and JNK3 are specifically inhibited by TCS JNK 5a. With pIC50 values of 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1, and p38α, respectively, TCS JNK 5a demonstrated selective against JNK1 and p38α. TCS JNK 5a also had pIC50 values below 5.0 at EGFR, ErbB2, VegFr2, Src, Tie-2, Alk5, c-Fms, CDK-2, GSK3β and PLK1.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C20H16N2OS
|
|
|---|---|---|
| Molecular Weight |
332.42
|
|
| Exact Mass |
332.10
|
|
| Elemental Analysis |
C, 72.26; H, 4.85; N, 8.43; O, 4.81; S, 9.64
|
|
| CAS # |
312917-14-9
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CCC2=C(C1)C(=C(S2)NC(=O)C3=CC=CC4=CC=CC=C43)C#N
|
|
| InChi Key |
WQGDQGAFSDMBLA-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H16N2OS/c21-12-17-15-9-3-4-11-18(15)24-20(17)22-19(23)16-10-5-7-13-6-1-2-8-14(13)16/h1-2,5-8,10H,3-4,9,11H2,(H,22,23)
|
|
| Chemical Name |
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)naphthalene-1-carboxamide
|
|
| Synonyms |
JNK Inhibitor IX; CS JNK 5a; TCS-JNK-5a; SC 202671; SC202671; SC-202671
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0082 mL | 15.0412 mL | 30.0824 mL | |
| 5 mM | 0.6016 mL | 3.0082 mL | 6.0165 mL | |
| 10 mM | 0.3008 mL | 1.5041 mL | 3.0082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA